BMS Prepares Orencia Launch In Japan, Aiming For First-line RA Treatment
This article was originally published in PharmAsia News
Executive Summary
Nagoya University medical professor Naoki Ishimuro said new rheumatoid drug Orencia (abatacept) will bring benefits to patients who are not responding to current therapies
You may also be interested in...
‘Parity To The Originator Is Not Enough’ – Cardinal Health Talks US Biosimilars
Following what Cardinal Health described as “a year of monumental developments in biosimilars,” the firm’s director of biosimilars, Dracey Poore, spoke to Generics Bulletin for an exclusive Q&A.
Fresenius And Formycon Strike Stelara Settlement For Europe And Canada
Partners Fresenius Kabi and Formycon have laid the groundwork to launch their biosimilar ustekinumab rival to Stelara in Europe and Canada through a settlement agreement with originator J&J.
Sumitomo To Reprioritize Pipeline After Ulotaront’s Phase III Fail
Sumitomo Pharma is to focus more on late-stage candidates in oncology and cell/gene therapy while passing on full global rights for ulotaront and SEP-380135 to Otsuka.